Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS – Q1 2019 REVENUES REACH A RECORD HIGH OF $9.1 M, A 43% INCREASE

14 January 2019

Quebec City, Quebec, January 14, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the first quarter of 2019. Highlights Consolidated revenues totaled $9.1 M in the first quarter of 2019 compared with $6.4 M in the corresponding period in 2018, an increase of $2.7 M or 43% and…

Read more

OPSENS’ dPR OBTAINS CE MARKING TO SELL IN EUROPE

9 January 2019

Quebec City, Quebec, January 9, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has been granted CE marking for its diastolic pressure algorithm (“dPR”). Opsens’ dPR algorithm has been designed to assess intracoronary pressure with the heart at rest to diagnose coronary disease without the injection of heart-stimulating medication. Opsens’ diastolic pressure ratio…

Read more

OPSENS REPORTS Q4 and FY2018 RESULTS – RECORD ANNUAL REVENUE SURPASS $24 M AND RECORD QUARTERLY FFR REVENUES AT $4.1 M

28 November 2018

Quebec City, Quebec, November 28, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the fourth quarter and fiscal year ended August 31, 2018. Highlights for the quarter and for the year Fractional Flow Reserve (“FFR”) revenues reach $4.1 M in the fourth quarter of 2018 compared with $2.8…

Read more

OPSENS RECEIVES HEALTH CANADA APPROVAL FOR dPR INTENDED FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

27 November 2018

Quebec City, Quebec, November 27, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF)  announced today that it has obtained approval from Health Canada to market its dPR Proprietary Resting Index,  which measures intracoronary pressure and establishes a diagnosis with the heart at rest to guide the treatment of patients with coronary heart disease. dPR stands for Diastolic…

Read more

OPSENS – FIRST USE OF dPR FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

8 November 2018

Quebec City, Quebec, November 8, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) announces that its Diastolic Pressure Ratio called dPR, has been used for the first time by Dr. Hitoshi Matsuo, cardiologist and President of the Gifu Heart Center Japan. The measurement of Fractional Flow Reserve (“FFR”) as a method of assessing intracoronary pressure has gained credibility and popularity…

Read more

OPSENS – 50,000 PATIENTS DIAGNOSED WITH THE OPTOWIRE

1 November 2018

Quebec City, Quebec, November 1st, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has reached an important milestone with more than 50,000 patients assessed with the OptoWire™, a pressure guidewire used to measure Fractional Flow Reserve (“FFR”) to diagnose and treat cardio vascular disease. The use of pressure guidewires to measure FFR for…

Read more

OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS

3 October 2018

OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS Quebec City, Quebec, October 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) will host an investor webinar and live Q&A session on Thursday, October 4, 2018, at 4.05 p.m. EST. The webinar will feature a presentation by…

Read more

OPSENS – NEW PRODUCT FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

20 September 2018

Quebec City, Quebec, September 20, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces it has developed a product that will allow the diagnosis of coronary heart blockages with the heart at rest. Filing for regulatory approvals has been completed in targeted territories. Opsens plans to begin commercialization by the end of calendar…

Read more

VISIT OPSENS AT TCT 2018

4 August 2018

Learn more about the benefits of OptoWire® as a workhorse wire at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference by visiting Opsens at their booth (#1907) or attend the complimentary educational lunch symposium. RSVP Now!  Educational Lunch Symposium “FFR and Non-Hyperemic Pressure Ratios: Start Right, Finish Right” Sponsored by Opsens Medical Sunday, September 23, 2018 11:30 a.m. – 12:30 p.m. Presentation…

Read more

OPSENS REPORTS Q3 2018 RESULTS – Quarterly Revenues Eclipse $6.4 M

12 July 2018

Quebec City, Quebec, July 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the third quarter ended May 31, 2018. Highlights for the quarter Consolidated revenues reached $6,398,000 for the three-month period compared with $4,892,000 for the same period last year, an increase of $1,506,000 or 31%; Consolidated…

Read more